A Randomized, Double-blind, Placebo Controlled Study of the Effectiveness of Chronic Incretin-based Therapy on Insulin Secretion in Cystic Fibrosis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Mar 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sitagliptin (Primary)
Indications Cystic fibrosis; Type 1 diabetes mellitus; Type 2 diabetes mellitus
Focus Adverse reactions; Pharmacodynamics

18 Aug 2021 Results published in the Journal of Clinical Endocrinology and Metabolism
22 May 2021 Primary endpoint (Change in second-phase insulin response derived from the glucose-potentiated arginine test as a measure of -cell sensitivity to glucose at baseline and at 6 months) has not been met according to the results published in the Journal of Clinical Endocrinology and Metabolism
22 May 2021 Results published in the Journal of Clinical Endocrinology and Metabolism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com